Natixis trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 20.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,073 shares of the company’s stock after selling 4,972 shares during the quarter. Natixis owned approximately 0.06% of TransMedics Group worth $1,410,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in TMDX. Venturi Wealth Management LLC bought a new stake in TransMedics Group during the first quarter worth about $30,000. Fidelis Capital Partners LLC acquired a new position in shares of TransMedics Group during the first quarter worth approximately $35,000. First Horizon Advisors Inc. lifted its position in shares of TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares in the last quarter. Entropy Technologies LP acquired a new position in shares of TransMedics Group during the first quarter worth approximately $201,000. Finally, SG Americas Securities LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth approximately $204,000. 99.67% of the stock is owned by institutional investors.
TransMedics Group Trading Down 2.1 %
NASDAQ TMDX traded down $3.20 during trading hours on Thursday, hitting $145.99. The company’s stock had a trading volume of 470,454 shares, compared to its average volume of 739,061. The stock has a fifty day moving average of $143.16 and a 200 day moving average of $108.24. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $156.05. The firm has a market capitalization of $4.81 billion, a P/E ratio of -429.38 and a beta of 1.98. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18.
Insider Buying and Selling at TransMedics Group
In other TransMedics Group news, Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the sale, the director now owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the sale, the director now owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 63,260 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the sale, the insider now directly owns 9,792 shares of the company’s stock, valued at approximately $1,062,823.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 247,667 shares of company stock valued at $30,087,968. Corporate insiders own 7.00% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. Stephens assumed coverage on shares of TransMedics Group in a research report on Tuesday, June 4th. They set an “overweight” rating and a $151.00 target price on the stock. Piper Sandler upped their target price on shares of TransMedics Group from $120.00 to $170.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $146.38.
Check Out Our Latest Analysis on TransMedics Group
TransMedics Group Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
See Also
- Five stocks we like better than TransMedics Group
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Want to Profit on the Downtrend? Downtrends, Explained.
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.